Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton's Tyrosine Kinase Inhibitor in Canada.
For patients with Mantle Cell Lymphoma (MCL), there is no recognized standard of care for relapsed/refractory (R/R) disease after treatment with a Bruton's tyrosine kinase inhibitor (BTKi). Brexucabtagene autoleucel (brexu-cel) represents a promising new treatment modality in MCL. We explored whethe...
| Publicado en: | Current Oncology Vol. 29; no. 3; pp. 2021 - 2046 |
|---|---|
| Autores principales: | , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
MDPI
Mar2022
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=156002900&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 156002900 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11980052 5EKK jtl: Current Oncology issn: 11980052 maglogo: N pubinfo: dt: Mar2022 vid: 29 iid: 3 pid: 97109 pub: MDPI artinfo: ui: 156002900 156002900 156002900 10.3390/curroncol29030164 156002900 ppf: 2021 ppct: 25 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton's Tyrosine Kinase Inhibitor in Canada. aug: au: Ball, Graeme Lemieux, Christopher Cameron, David Seftel, Matthew D. affil: Gilead Sciences Canada, Inc., Mississauga, ON L5N 2W3, Canada sug: subj: Neoplasm Recurrence, Local Therapy Drug Resistance, Neoplasm Lymphoma, Non-Hodgkin's Therapy Tyrosine Kinase Inhibitors Therapeutic Use Antineoplastic Agents Therapeutic Use Cost Benefit Analysis Lymphoma, Non-Hodgkin's Economics Immunotherapy Economics Gene Therapy Economics Biological Products Therapeutic Use Palliative Care Economics Biological Products Economics Human Lymphoma, Non-Hodgkin's Prognosis Cancer Patients Descriptive Statistics Treatment Outcomes Quality-Adjusted Life Years Comparative Studies Canada ab: For patients with Mantle Cell Lymphoma (MCL), there is no recognized standard of care for relapsed/refractory (R/R) disease after treatment with a Bruton's tyrosine kinase inhibitor (BTKi). Brexucabtagene autoleucel (brexu-cel) represents a promising new treatment modality in MCL. We explored whether brexu-cel was cost-effective for the treatment of R/R MCL. We developed a partitioned survival mixture cure approach to model the costs and outcomes over a lifetime horizon. The clinical data were derived from the ZUMA-2 clinical trial. The costs were estimated from the publicly available Canadian databases, published oncology literature, and pan-Canadian Oncology Drug Review economic guidance reports. The health state utilities were sourced from the ibrutinib submission to the National Institute for Health and Care Excellence for R/R MCL and supplemented with values from the published oncology literature. In the base case over a lifetime horizon, brexu-cel generated an incremental 9.56 life-years and an additional 7.03 quality-adjusted life-years compared to BSC, while associated with CAD 621,933 in additional costs. The resultant incremental cost-utility ratio was CAD 88,503 per QALY gained compared with BSC. Based on this analysis, we found brexu-cel to be a cost-effective use of healthcare resources relative to BSC for treatment of adult patients with R/R MCL previously treated with a BTKi in Canada, though additional research is needed to confirm these results using longer follow-up data. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|